Similar to the situation in schwannomatosis patients, the loss of both Smarcb1 and Nf2 did not increase the malignancy of the tumours in mGFAP-Cre; Smarcb1flox/flox;Nf2flox/flox mice as compared to tumours in mGFAP-Cre; Nf2flox/flox mice with biallelic Nf2 loss but retention of Smarcb1 activity. This evidence concerns the gene SMARCB1 and schwannomatosis.